If 23andMe is sold, merges with another company, or goes through bankruptcy, your genetic and personal data may be transferred to the new owner as part of that transaction.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This provision is particularly significant given that 23andMe has publicly reported financial difficulties; it means your most sensitive personal data, your DNA, could be acquired and controlled by an entity you did not originally consent to share it with.
Interpretive note: The document's summary version references account deletion and data discard but the full business transfer clause language was truncated in the provided document; the provision's exact scope is inferred from standard 23andMe policy language and the document context.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth …
The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for teleheal…
The agreement authorizes transfer of genetic information, self-reported health data, and account data to a successor entity in a merger, acquisition, or bankruptcy proceeding, and users have limited ability to prevent this transfer once it occurs, though deletion prior to such a transaction would remove their data from the transferred assets.
How other platforms handle this
In connection with any reorganization, restructuring, merger or sale, or other transfer of assets, we will transfer information, including personal information, provided that the receiving party agrees to respect your personal information in a manner that is consistent with our Privacy Policy.
Where required by law, we provide adequate protection for the transfer of personal data in accordance with applicable law, such as by obtaining your consent, relying on the European Commission's adequacy decisions, or executing Standard Contractual Clauses. Where relevant, you may request a copy of ...
We may transfer to and process your personal information in countries outside of the jurisdiction where you are located for the various purposes described above. When required by law, we will ensure that we rely on an appropriate legal mechanism for the transfer, such as your consent, standard contr...
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 10 platforms.
"You can delete your 23andMe account any time. If you do, we will automatically opt you out of Research and discard your sample. Keep in mind this process cannot be cancelled or reversed.— Excerpt from 23andMe's 23andMe Privacy Statement
REGULATORY LANDSCAPE: Business transfer clauses involving genetic data engage GDPR Article 6 lawful basis requirements and Article 9 for special category data, as a change of data controller in an acquisition or bankruptcy typically requires assessment of whether the original consent basis extends to the new controller. The FTC has historically scrutinized data transfers in bankruptcy proceedings where assets include sensitive personal data. California CCPA and the California Genetic Information Privacy Act may also impose obligations on successor entities that acquire California residents' genetic data. GOVERNANCE EXPOSURE: High. Transfer of genomic data to a successor entity without requiring fresh consent from users creates material regulatory exposure under GDPR and may engage FTC scrutiny under the FTC Act's unfair practices authority, particularly if the successor entity's intended use of the data differs from the original consent. The sensitivity of genomic data amplifies this exposure relative to standard business transfer clauses. JURISDICTION FLAGS: EU and UK users are subject to GDPR and UK GDPR, which impose strict controller-change notification and lawful basis requirements. California residents may have rights under CCPA to opt out of sale or transfer. The bankruptcy context may also trigger court supervision of data transfer under US bankruptcy law, and the FTC has intervened in prior consumer data bankruptcies. CONTRACT AND VENDOR IMPLICATIONS: Procurement and M&A teams reviewing any transaction involving 23andMe should treat the genomic data asset as requiring specialized due diligence. The transferability of user consent obtained under the current policy to a successor entity is a material open question that should be addressed in transaction documents and any regulatory notifications. COMPLIANCE CONSIDERATIONS: Legal teams should evaluate whether pre-transaction user notification and opt-out mechanisms are required under applicable law before any business transfer closes. Data mapping should identify the volume and categories of genetic and health data subject to transfer. EU and UK regulatory authorities may require notification of a controller change. A fresh consent mechanism for Research participation post-transfer may be legally necessary under GDPR.
Full compliance analysis
Regulatory citations, enforcement risk, and due diligence action items.
Free: track 1 platform + weekly digest. Watcher: 10 platforms + same-day alerts. No credit card required.
ConductAtlas detected a major restructuring of Meta’s privacy policy that removed detailed consumer rights disclosures and relocated them to separate documents.
Your genetic data may be transferred to a new owner as a business asset. Here is what the Terms of Service actually say and what you can do right now.
Professional Governance Intelligence
Need to monitor specific governance provisions?
Professional includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
This provision is particularly significant given that 23andMe has publicly reported financial difficulties; it means your most sensitive personal data, your DNA, could be acquired and controlled by an entity you did not originally consent to share it with.
The agreement authorizes transfer of genetic information, self-reported health data, and account data to a successor entity in a merger, acquisition, or bankruptcy proceeding, and users have limited ability to prevent this transfer once it occurs, though deletion prior to such a transaction would remove their data from the transferred assets.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.